Health Care & Life Sciences » Biotechnology | Celldex Therapeutics Inc.

Celldex Therapeutics Inc.

Celldex Therapeutics Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
162.44 M
Public Float
142.74 M
Celldex Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$4.52
Market Cap
$31.62 M
Shares Outstanding
13.77 M
Public Float
12.07 M

Profile

Address
Perryville III Building
Hampton New Jersey 08827
United States
Employees -
Website http://www.celldex.com
Updated 09/14/2018
Celldex Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes therapeutic antibodies, antibody drug conjugates, vaccines, and immune system modulators. The company's drug candidates include Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, and Rintega.

Financials

View All
Created with Highcharts 5.0.14Celldex Therapeutics Inc.Net Income. Fiscal year is January-December. All values USD Thousands.81 55081 550118 080118 080127 197127 197128 530128 53093 03193 03120132014201520162017025k50k75k100k125k150k
Created with Highcharts 5.0.14Celldex Therapeutics Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.4 1114 1113 5863 5865 4805 4806 7866 78612 74312 7432013201420152016201702.5k5k7.5k10k12.5k15k

Anthony S. Marucci
President, Chief Executive Officer & Director
Herbert J. Conrad
Director